CytomX Therapeutics (NASDAQ:CTMX) Given New $11.00 Price Target at JPMorgan Chase & Co.Market Beat·Aug 13 at 10:36 AMCTMX-0.30%
CytomX Therapeutics (NASDAQ:CTMX) Announces Earnings ResultsMarket Beat·Aug 7 at 11:41 PMCTMX-0.30%REGN+0.90%
CTMX: Varseta-M advances in CRC and GI cancers, supported by strong cash and expanded Regeneron collaborationQuartr·Aug 6 at 06:08 PMCTMX-0.30%REGN+0.90%
Cytomx Therap | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 1.418 MEarnings Watch·Aug 6 at 03:46 PMCTMX-0.30%
CytomX Q2 FY26 net loss widens to $20.67 million; revenue drops to $1.42 millionPUBT·Aug 6 at 03:24 PMCTMX-0.30%
CytomX Therapeutics Chief Legal Officer Alejandra Carvajal files initial beneficial ownership statementPUBT·Aug 5 at 06:32 PMCTMX-0.30%
CytomX Therapeutics, Inc. $CTMX Shares Bought by Perceptive Advisors LLCMarket Beat·Aug 2 at 05:08 AMCTMX-0.30%
CytomX Therapeutics director Charles S. Fuchs files initial beneficial ownership statementPUBT·Jul 30 at 04:23 PMCTMX-0.30%
CytomX Therapeutics (CTMX) Projected to Announce Quarterly Earnings on ThursdayMarket Beat·Jul 30 at 04:56 AMCTMX-0.30%
